Format

Send to:

Choose Destination
See comment in PubMed Commons below
Fundam Clin Pharmacol. 2007 Nov;21 Suppl 2:15-8.

Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels.

Author information

  • 1Service d'Endocrinologie, Diabétologie et Maladies Métaboliques, Hôpital du Bocage, C.H.U. Dijon, France. bruno.verges@chu-dijon.fr

Abstract

Both pioglitazone and rosiglitazone are effective hypoglycaemic agents in monotherapy as in combined therapy. Interestingly, their reducing effect on fasting glycaemia and HbA1c is maintained over time, suggesting a potential protective effect of glitazones on the pancreatic beta-cells. The effects on lipids of pioglitazone are more favourable than those of rosiglitazone. Indeed, pioglitazone appears to be well suited for diabetic dyslipidaemia, increasing high-density lipoprotein (HDL)-cholesterol, decreasing triglycerides and small, dense low-density (LDL) particles with usually no effect on plasma LDL-cholesterol. Rosiglitazone also increases HDL-cholesterol, but has no effect on triglycerides and increases plasma LDL-cholesterol.

PMID:
18001314
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk